Trump Announces Staged Tariff Plan on Imported Generic Drugs to Spur Domestic Manufacturing

President Donald Trump announced on Tuesday that imported generic drugs will remain tariff‑free for the next two years before facing steep new import duties, a move intended to incentivize pharmaceutical firms to shift more production to the United States.

In a Truth Social post, he said that all generic drugs entering the U.S. will continue to be subject to a 0 % tariff starting August 1, 2026, for a two‑year transition period. After that, the tariff will climb to 100 % for one year and then to 200 % thereafter.

“Effective August 1, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two‑year period, after which the TARIFF will be raised to 100 % for one year and then to 200 %,” Trump wrote.

He explained that the phased approach gives drugmakers time to relocate production to the U.S. before the higher duties take effect.

President Donald Trump gestures while meeting with Lebanese President Joseph Aoun in the Oval Office at the White House on Tuesday. (Aaron Schwartz/CNP/Bloomberg via Getty Images / Getty Images)

“This policy is designed to reshore generic pharmaceutical production into America, imposing penalties on companies that decline to build plants and equipment within the allotted timeframe,” Trump stated.

He added that the goal of the measure is “to protect the people of the United States.”

The announcement represents the latest effort by the Trump administration to use tariffs as leverage to encourage domestic manufacturing in sectors deemed strategically important, such as pharmaceuticals. Officials have repeatedly warned that the United States relies too heavily on foreign sources for essential medicines and active pharmaceutical ingredients.

Trump noted that his administration’s current policy concerning patented, branded and innovative drugs will remain unchanged.

Boxes of generic prescription drugs and blister packs of tablets from Tehatta, India. President Donald Trump announced a phased tariff plan on imported generic drugs aimed at encouraging pharmaceutical manufacturing in the United States. (Soumyabrata Roy/Majority World/Universal Images Group via Getty Images  / Getty Images)

“The policy on patented, branded, or innovative drugs, which has proven successful, will stay exactly as it is,” he said.

He also highlighted a surge in domestic investment by drugmakers.

“Pharmaceutical facilities are being constructed at an unprecedented rate across the United States,” Trump wrote.

The Association for Accessible Medicines, which represents generic drug manufacturers, said it is seeking further details on the proposal but backs policies that strengthen U.S. production.

“We need to understand the specifics of the policy, but the generics industry is committed to pursuing measures that support and stabilize both the sector and patient access to affordable medicines,” said John Murphy III, president and CEO of the Association for Accessible Medicines, in a statement shared with FOX Business.

Murphy noted that while the industry has expanded its U.S. manufacturing investments over the past two years, structural challenges related to purchasing and reimbursement continue to impede further growth. He expressed optimism about collaborating with the administration and Congress to bolster the domestic generic drug sector.

Capsules move along a production line at a Sanofi pharmaceutical manufacturing facility in Lisieux, France. President Donald Trump announced a phased tariff plan on imported generic drugs aimed at encouraging pharmaceutical manufacturing in the U.S. (Lou Benoist/AFP via Getty Images, File / Getty Images)

Generic drugs account for more than 90 % of prescriptions filled in the United States, according to the Food and Drug Administration.

Many manufacturers also depend on global supply chains and imported active pharmaceutical ingredients, making supply‑chain resilience an increasing priority for policymakers and the pharmaceutical industry.

The announcement provides a two‑year window before tariffs rise, giving companies time to decide whether to build or expand U.S. production facilities or continue importing while facing substantially higher duties.

Source link